Principal Investigator
Alejandra Perez
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20220744
Clinical Trial Summary
Randomized phase 2 clinical trial of nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab in patients with metastatic triple negative breast cancer
Phase
Phase II
Funding Agency/Sponsor
National Cooperative Group
Disease
Breast Cancer
Contact Information
Phone Number
305-243-2647